Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
While amphotericin B is the drug of choice in the treatment of most fungal infections, systemic adverse reactions and dose-dependent nephrotoxicity associated with its use frequently render the conventional preparation of amphotericin unsuitable. A number of lipid-based formulations of amphotericin have been developed to overcome the limitations of the parent compound. These preparations, amphotericin B lipid complex (ABLC), amphotericin B colloid dispersion (ABCD) and liposomal amphotericin differ from one another significantly in their molecular structure. They are also considerably more expensive than the parent compound. Clinical data on their appropriate use are limited. This review looks at the differences in molecular structure of these preparations, and at the available clinical safety and efficacy data.
Mehta
J
J
Leukaemia Unit, Royal Marsden Hospital, Sutton, Surrey, U.K.
D000666:Amphotericin B / Q000031:analogs & derivatives*; D000935:Antifungal Agents; D002788:Cholesterol Esters; D004338:Drug Combinations; D006801:Humans; D015394:Molecular Structure; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D013329:Structure-Activity Relationship
D000935:Antifungal Agents; D002788:Cholesterol Esters; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B